Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the humanized amyloid-beta (Aβ) monoclonal antibody “Leqembi®” (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great […]

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) reconfirmed today that the regulatory
status for anti-amyloid beta (Aβ) protofibril antibody LEQEMBI® (generic name: lecanemab) subcutaneous
(SC) autoinjector, explained at the Financial Disclosure Meeting on August 2, 2024, is as follows.

Eisai and Biogen announced today that the Ministry of Food and Drug Safety
(MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Aβ)
monoclonal antibody “LEQEMBI®” (lecanemab) for treatment in adult patients with mild cognitive
impairment due to Alzheimer’s disease (AD) or mild AD (early AD).

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa® (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan.